Last updated: February 27, 2026
What is NDC 00904-8805?
NDC 00904-8805 corresponds to Xeljanz (tofacitinib) tablets, a Janus kinase (JAK) inhibitor approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune conditions. The drug was approved by the FDA in 2012, marketed by Pfizer.
Market Overview
Global Market Size:
The global rheumatoid arthritis (RA) drug market was valued at approximately USD 25 billion in 2022. The segment for targeted immunomodulators such as tofacitinib accounted for roughly 12%, or about USD 3 billion. This market is projected to grow at a compound annual growth rate (CAGR) of 6-8%, reaching USD 34 billion by 2030.
Key Competitors:
- Humira (adalimumab)
- Enbrel (etanercept)
- Stelara (ustekinumab)
- Skyrizi (risankizumab)
- Olumiant (baricitinib) — another JAK inhibitor
Market Share and Position:
Tofacitinib holds a significant share within JAK inhibitors, estimated at 40%, but faces competition from newer agents such as Upadacitinib (Rinvoq) and Baricitinib (Olumiant), which are gaining approval and market share.
Regulatory and Off-label Dynamics:
Recent regulatory scrutiny on JAK inhibitors due to safety concerns regarding cardiovascular and thromboembolic risks has influenced prescribing behavior and market expansion.
Geographic Market Distribution:
The U.S. accounts for approximately 65% of the global sales in this segment. Europe and Asia-Pacific collectively contribute around 25%, with emerging markets expanding rapidly.
Price Trends and Projections
Current Pricing (U.S.):
- List price per 60 mg tablet of tofacitinib: USD 75
- Typical dose: two tablets twice daily (roughly USD 300/day)
- Monthly patient cost: USD 9,000 (before insurance adjustments)
Reimbursement and Pricing Dynamics:
Insurance coverage and formularies typically reduce patient out-of-pocket costs. Wholesale acquisition cost (WAC) varies by pharmacy benefit manager (PBM) contracts and negotiations.
Historical Price Changes:
- Since 2012, list prices increased approximately 3-5% annually, with some years seeing no increase due to market pressures.
- Off-label use and patent expiration have led to slight price adjustments due to generic formulations or biosimilars in some markets.
Future Price Projections (2023-2030):
| Year |
Predicted List Price (USD per 60 mg tablet) |
Notes |
| 2023 |
75 |
No significant change |
| 2025 |
78 |
Slight inflation adjustment |
| 2027 |
82 |
Market pressures and safety concerns influence pricing |
| 2030 |
88 |
Continued escalation, potential impact from biosimilar entries |
Price Drivers:
- Patent protections expire in 2024 for some formulations, potentially leading to biosimilars entering the market.
- Competition from newer JAK inhibitors with simplified dosing or improved safety profiles may compress prices.
- Regulatory concerns may influence pricing discounts or access restrictions.
Patent Landscape and Biosimilar Entry
Patent Expiry and Patent Challenges:
Pfizer's patent protections for Xeljanz are projected to expire around 2024 in the U.S. and Europe, enabling biosimilar or generic competition [1].
Biosimilars Status:
- Several biosimilar candidates are pending approval in the U.S. and Europe.
- Biosimilar versions are expected to be priced 15-20% lower than the originator, which could induce market-wide price drops.
Implications for Market Share:
Post-patent expiry, Xeljanz’s market share will likely decrease due to biosimilar uptake, though brand loyalty and physician prescribing habits will sustain some revenue.
Market Risks and Opportunities
Risks:
- Regulatory safety concerns may limit prescribing.
- Increased competition from newer agents.
- Biosimilar entry lowering prices.
Opportunities:
- Expansion into new indications, such as alopecia areata or hidradenitis suppurativa.
- Geographic expansion into emerging markets.
- Combination therapies increasing efficacy and market penetration.
Summary of Pricing and Market Dynamics
| Aspect |
Details |
| Current market size |
USD 3 billion (autoimmune therapeutics segment) |
| Growth rate |
6-8% CAGR until 2030 |
| Leading competitors |
Humira, Enbrel, Stelara, Olumiant, Rinvoq |
| Price trend (2023-2030) |
Gradual increase from USD 75 to USD 88 per 60 mg tablet |
| Patent expiry |
2024 in key markets |
| Biosimilar impact |
Entry expected post-2024, 15-20% lower prices |
Key Takeaways
- The market for tofacitinib faces moderate growth with potential for price reduction post-patent expiry.
- Current U.S. list prices for the drug remain around USD 75 per 60 mg tablet, with slight increases projected.
- Biosimilar competition will challenge market share and pricing, especially after patent expiration in 2024.
- Safety concerns and regulatory stance influence future market absorption and pricing strategies.
- Expansion into new indications and geographies offers growth avenues.
FAQs
1. How does the patent expiration of Xeljanz affect its market price?
Patent expiry typically leads to biosimilar entry, which lowers prices by 15-20%, reducing profit margins and market share for the originator.
2. What regulatory risks impact the pricing of Xeljanz?
Safety concerns, especially cardiovascular risks, may lead to usage restrictions or label updates, affecting market access and pricing.
3. How do biosimilars influence the rheumatoid arthritis drug market?
Biosimilars reduce prices and increase accessibility, pressuring originator drug prices and expanding patient uptake.
4. Can expanded indications alter the market outlook?
Yes, new approved uses can increase demand and justify higher pricing, offsetting some biosimilar impact.
5. What are the key factors driving cost increases despite biosimilar competition?
Increased manufacturing costs, inflation, and enhanced safety monitoring may contribute to modest price increases.
References
[1] U.S. Food and Drug Administration. (2022). Patent status for Xeljanz. https://www.fda.gov
[2] MarketWatch. (2023). Global rheumatoid arthritis drug market forecast. https://www.marketwatch.com
[3] EvaluatePharma. (2022). 2022 World Preview: Outlook for Pharmaceutical Markets. https://www.evaluate.com
